Deepak Srivastava
Deepak Srivastava (born May 14, 1966) is the president of Gladstone Institutes, where he is also a senior investigator and the Robert W. and Linda Mahley Distinguished Professor. Additionally, he is director of the Roddenberry Stem Cell Center at Gladstone. At UC San Francisco, with which Gladstone is affiliated, Srivastava is a professor in the Department of Pediatrics and the Department of Biochemistry and Biophysics. He is also the Wilma and Adeline Pirag Distinguished Professor in Pediatric Developmental Cardiology, and an attending physician in pediatric cardiology at UCSF Benioff Children’s Hospitals.[1]
Srivastava's laboratory focuses on understanding the causes of heart disease and on using knowledge of cardiac developmental pathways to devise novel therapeutic approaches for human cardiac disorders.[2][3] The family settled in Los Angeles, where Srivastava’s father had joined the faculty at City of Hope Medical Center.[2] Eight years later, they moved to Texas so his father could accept a professorship at the University of Texas Medical Branch in Galveston.[2]
Early Life
Born in India, Srivastava immigrated to the United States with his father, a biochemist, his mother, a teacher, and his two older sisters when he was under one year of age.[2][3] The family settled in Los Angeles, where Srivastava’s father had joined the faculty at City of Hope Medical Center.[2] Eight years later, they moved to Texas so his father could accept a professorship at the University of Texas Medical Branch in Galveston.[2]
Education and early career
Srivastava completed his schooling in Texas, eventually earning a bachelor’s degree in biochemistry at Rice University.[4] Citing an early interest in medicine and wanting to help people,[3] Srivastava went on to earn his medical degree at The University of Texas Medical Branch. It was during medical school that he became interested in genome regulation and its link to disease.[5] He performed his residency in pediatrics at UC San Francisco and, mentored by notable professors such as Larry Shapiro, Abraham Rudolph, and Julien Hoffman, solidified an interest in pediatric cardiology.[2]
Srivastava completed a fellowship in pediatric cardiology at Boston Children’s Hospital of Harvard Medical School and then, inspired by the work of molecular biologist Eric Olson, completed another fellowship in Olson’s lab at MD Anderson Cancer Center.[2][5] Together, they mapped the key transcription factors directing heart development.[5]
In 1996, Deepak was appointed associate professor, rising to professor, in the Departments of Pediatrics and Molecular Biology at UT Southwestern Medical Center.[6] He led his own lab there until being recruited to San Francisco in 2005 to direct the Gladstone Institute of Cardiovascular Disease. He was named president of Gladstone Institutes in 2018, becoming the third president in the organization’s history.[7]
Leadership
After taking the helm at Gladstone, Srivastava began expanding the organization’s scientific capabilities. He established the Gladstone Institute of Data Science and Biotechnology in 2018 and the Gladstone-UCSF Institute of Genomic Immunology in 2020. He recruited two scientists who went on to become Nobel laureates: stem cell expert Shinya Yamanaka and Jennifer Doudna, co-inventor of the CRISPR gene editing technology.[2][5][8] He also added a number of early career scientists from varied disciplines to Gladstone’s laboratory teams.[3]
In 2022, Srivastava announced plans to further extend Gladstone’s footprint by adding more than a dozen new labs and recruiting hundreds of new scientists, and to deepen the organization’s expertise in the areas of AI and clinical translation.[9][10][8][11] In 2024, the San Francisco Business Times named him one of the Bay Area’s most admired CEOs.[12]
Research
Srivastava’s research is focused on gene networks that guide development of the heart, seeking to understand how aberrations in these pathways can cause congenital heart disease, and how they can use this knowledge to generate new cardiac cells to repair heart damage.[2][5][4]
In 2018, Srivastava discovered a way to regenerate adult heart tissue that had been scarred by a heart attack. He isolated four genes that are turned on in a developing fetus to form the heart, but are switched off at birth to stop heart cells from continuing to divide. By reactivating those genes, he was able make them divide again, converting cells into new muscle.[13] His discovery was published in the scientific journal Cell.[14]
Srivastava also identified genetic mechanisms that explain why babies born to women with diabetes are five times more likely to have a congenital heart defect.[15] The study, published in the scientific journal Nature Cardiovascular Research, provides a template for using single-cell-based studies to link environmental factors and birth defects more broadly.[16]
During his career, Srivastava has published close to 240 peer-reviewed, highly cited articles. He has served as president of the International Society for Stem Cell Research[17] and he contributes to the editorial board of scientific journal Cell Stem Cell.
Commercial Activities
Srivastava has co-founded two biotechnology companies: iPierian Inc.,[18] acquired by Bristol Myers Squibb in 2014,[19][20][21] and Tenaya Therapeutics,[5][22][23] which is developing therapies that address the underlying drivers of heart disease. Srivastava serves on Tenaya’s board of directors as well as its scientific advisory board.
Personal Life
During his pediatric residency at UC San Francisco, Srivastava met and married Denise Maher, a nurse in the neonatal intensive care unit there. They had three children and spent more than 30 years together before she passed away unexpectedly in 2023. Srivastava lives in San Francisco.[24]
Awards and Honors
2023 Distinguished Scientist Award, American Heart Association
2020 Distinguished Alumnus Award, Rice University
2017 Upstart 50 Inventor Award, San Francisco Business Times
2016 Andras Varro Award for Excellence in Cardiovascular Sciences, International Academy of Cardiovascular Sciences
2014 Elected member, National Academy of Medicine
2014 Elected member, International Academy of Cardiovascular Sciences
2013 Pantheon Award for Scientific Achievement, BayBio Institute
2013 Best Manuscript Award, Circulation Research
2013 Outstanding Investigator Award, International Society for Heart Research
2013 Ashbel Smith Distinguished Alumnus Award, University of Texas Medical Branch
2012 Elected member, American Pediatric Society
2012 Abraham White Scientific Achievement Award, The George Washington University
2011 Elected fellow, American Association for the Advancement of Science
2010 Elected fellow, American Heart Association
2010 Elected member, American Academy of Arts and Sciences
2007 E. Mead Johnson Award, Society for Pediatric Research
2004 Elected member, American Society for Clinical Investigation
2004 Elected member, Society for Pediatric Research
2004 Outstanding Contributions in Medicine Award, Dallas Asian American Chamber of Commerce
1998 Richard Rowe Award, Society for Pediatric Research
1998 Young Investigator Award, Perinatal Research Society
1995 Young Investigator Award, American Heart Association
1995 Basic Science Research Award, Society for Pediatric Research
1993 Pediatric Scientist Development Award, National Institutes of Health
References
- ↑ "Deepak Srivastava « World Alliance Forum in San Francisco". Retrieved 2024-08-12.
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 Williams, Ruth (2014-08-15). "Deepak Srivastava: Follows His Heart to Study the Heart". Circulation Research. 115 (5): 481–483. doi:10.1161/CIRCRESAHA.114.304793. ISSN 0009-7330. PMID 25124324.
- ↑ 3.0 3.1 3.2 3.3 Grewal, Seema (15 June 2015). "An interview with Deepak Srivastava". Development. 142 (12): 2083–2084. doi:10.1242/dev.125468. PMID 26081568 – via The Company of Biologists.
- ↑ 4.0 4.1 "2020-2021 Laureates Award Honorees". Rice University.
- ↑ 5.0 5.1 5.2 5.3 5.4 5.5 Neel, Dylan (2023-01-10). "Lab Meeting: Deepak Srivastava". Biomarker. Retrieved 2024-08-27.
- ↑ "Movers". Nature. 434 (7029): 120. March 2, 2005. doi:10.1038/nj7029-120c. ISSN 1476-4687.
- ↑ "San Francisco Business Times". www.bizjournals.com. Oct 5, 2017. Retrieved 2024-09-20.
- ↑ 8.0 8.1 "San Francisco Business Times". www.bizjournals.com. May 9, 2024. Retrieved 2024-09-20.
- ↑ Hilgers, Laura (2022-11-03). "Medical Milestones Are Underway at San Francisco's Gladstone Institutes". nobhillgazette.com. Retrieved 2024-09-20.
- ↑ Staff, T. R. D. (2023-02-16). "Gladstone plans $160M expansion of Mission Bay headquarters". The Real Deal. Retrieved 2024-09-20.
- ↑ Nelson, Andrew (2023-02-16). "Gladstone Expansion Announced for 1650 Owens Street in Mission Bay, San Francisco". San Francisco YIMBY. Retrieved 2024-10-03.
- ↑ Leuty, Ron. "Gladstone's Deepak Srivastava is using collaboration to propel medical research". www.bizjournals.com. Archived from the original on May 10, 2024. Retrieved 2024-10-03. Unknown parameter
|url-status=ignored (help) - ↑ Park, Alice (2018-09-13). "Scientists Are Developing New Ways to Treat Disease with Cells, Not Drugs". TIME. Retrieved 2024-10-03.
- ↑ "Regulation of Cell Cycle to Stimulate Adult Cardiomyocyte Proliferation and Cardiac Regeneration". Retrieved March 22, 2018.
- ↑ Thomas, Uduak (2023-12-03). "Genetic Mechanisms Linking Maternal Diabetes and Birth Defects Uncovered". GEN - Genetic Engineering and Biotechnology News. Retrieved 2024-10-03.
- ↑ Nishino, Tomohiro; Ranade, Sanjeev S.; Pelonero, Angelo; van Soldt, Benjamin J.; Ye, Lin; Alexanian, Michael; Koback, Frances; Huang, Yu; Wallace, Langley Grace; Sadagopan, Nandhini; Lam, Adrienne; Zholudeva, Lyandysha V.; Li, Feiya; Padmanabhan, Arun; Thomas, Reuben (November 30, 2023). "Single-cell multimodal analyses reveal epigenomic and transcriptomic basis for birth defects in maternal diabetes". Nature Cardiovascular Research. 2 (12): 1190–1203. doi:10.1038/s44161-023-00367-y. ISSN 2731-0590. PMC 11343316 Check
|pmc=value (help). PMID 39183978 Check|pmid=value (help). - ↑ "ISSCR Presidents look back on their presidency, the evolution of the field, and the Society". Stem Cell Reports. 17 (6): 1237–1244. June 14, 2022. doi:10.1016/j.stemcr.2022.05.012. ISSN 2213-6711. PMC 9214063 Check
|pmc=value (help). PMID 35705012 Check|pmid=value (help). - ↑ Carroll, John (March 15, 2011). "Gladstone Institute's Deepak Srivastava joins Executive Breakfast panel". Fierce Biotech.
- ↑ "Bristol-Myers Squibb Acquires iPierian, Inc". Bristol-Myers Squibb. April 29, 2014.
- ↑ "BMS acquires outcomes tool for psychiatric disorders". PharmacoEconomics & Outcomes News. 51 (1): 7. April 29, 2014. doi:10.1007/bf03296111. ISSN 1173-5503 – via Genetic Engineering & Biotechnology News.
- ↑ "Crunchbase".
- ↑ Podcast, Stem Cell. "Ep. 165". The Stem Cell Podcast. Retrieved 2024-10-03.
- ↑ "Leadership | Tenaya Therapeutics". www.tenayatherapeutics.com. Retrieved 2024-10-03.
- ↑ "Denise Srivastava Obituary (1963 - 2023) - San Francisco, CA - San Francisco Chronicle". Legacy.com. Retrieved 2024-10-03.
This article "Deepak Srivastava" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Deepak Srivastava. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
